New hope for lung cancer patients whose targeted treatment has failed

This study tests a new drug called SKB264 against standard chemotherapy in 376 adults with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to targeted therapy. The goal is to see if SKB264 alone can better delay cancer growth or improve survival compared to standard chemo. Participants are randomly assigned to receive either SKB264 or chemo, and the study is open-label, meaning both doctors and patients know which treatment is given.